Immunology Respiratory Research
Find out more about our research and development in Immunology & Respiratory diseases
Search
Immunology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in immunology.
SIRPα Cancer Immunology Research
Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
Oncology and Cancer Immunology Research
Find out more about our research and development in oncology and cancer immunology.
Immunology
Immunology
Agreement-to-acquire-Labor-Dr.-Merk
Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen to strengthen its next generation cancer immunology program
Four Pillars Cancer Immunology
Boehringer Ingelheim is focusing cancer immunology research on T cell engagers, cancer vaccines, oncolytic viruses and immune & stromal modulation
Oncology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
Acquisition expands research in cancer immunology
Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
Translational Medicine in Immunology
Find out how translational medicine is helping bring transformational therapies to patients
Our transformative team culture
The immunology team is grounded in three key elements: Curiosity, creativity and courage. Hear about the culture at Boehringer Ingelheim.
Disentangling fibrosis
Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
Collaboration-with-OxfordBioTherapeutics
Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
Immunomodulator
Immunomodulator
Science Focus
Science Focus
TREM-1 Antibody
TREM-1 Antibody
PD-1 antibody
PD-1 antibody
Trailr2-cdh17-antibody-phase1-trial
Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
Spesolimab (BI 655130)
Spesolimab (BI 655130): IL36R antibody
Lung Repair & Regeneration Video
Lung repair & regeneration research addresses fundamental changes to lung architecture and how these changes impact lung function.